A model for cutaneous squamous cell carcinoma in vemurafenib therapy

Area of Science:

• Oncology
• Dermatology
• Pharmacology

Background:

• BRAF inhibitors (vemurafenib, dabrafenib) are FDA-approved for V600E-mutated metastatic melanoma.
• These targeted therapies are associated with secondary cutaneous malignancies, specifically squamous cell carcinoma and keratoacanthoma.
• Pathological studies indicate these secondary tumors exhibit de novo pathogenesis, lacking the primary cancer's mutations.

Observation:

• Pathological examination reveals that these treatment-induced tumors lack the BRAF V600E mutation found in the primary melanoma.
• This suggests an alternative, de novo pathway for the development of these secondary skin cancers.

Findings:

• The development of cutaneous squamous cell carcinoma and keratoacanthoma is a significant clinical observation in patients treated with BRAF inhibitors.
• The distinct mutational profile of these secondary tumors points to a pathogenesis independent of the original melanoma's genetic drivers.

Implications:

• Patients undergoing BRAF inhibitor therapy require vigilant dermatological surveillance to detect early signs of secondary skin cancers.
• Understanding the de novo pathogenesis of these tumors is crucial for refining management strategies and patient follow-up protocols.
• This highlights the importance of a multidisciplinary approach involving oncologists and dermatologists in managing patients on BRAF inhibitor therapy.